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Patient population demographics:
•
Average age of 59 years, a breakdown of 52% female to 48% male, and average BMI of 31.27
•
Chronic liver disease: non-alcoholic fatty liver disease (NAFLD) (62.59%), followed by Hepatitis C (20.41%)
and cirrhosis (15.65%)
•
LD patients were more likely to also have comorbid conditions such as hypertension, hyperlipidemia, type II
diabetes, and alcohol and tobacco use than those without chronic liver disease, as well as higher proportion
of cardiovascular risk factors than what has been documented by the county’s data of similar risk factors

The novel Coronavirus disease 2019 (COVID-19) caused by the SARSCoV-2 strain has resulted in more than 107 million confirmed cases of
infection worldwide and more than 2 million deaths as of February 2021.1
Preliminary studies of the disease and its outcomes showed that patients
with preexisting cardiovascular disease, pulmonary disease such as COPD
or asthma, and diabetes had more severe COVID-19 outcomes than those
without comorbid conditions.2 While the virus is mainly characterized by
respiratory symptoms and the potential progression to acute respiratory
distress syndrome (ARDS), additional organ involvement has also been
identified as a sequela of the virus. An estimated 20-30% of people infected
with COVID-19 also present with liver injury, which can manifest as an
elevation in liver enzymes and even pathological changes to the liver found
during autopsy.3 A retrospective study conducted in Italy by Piano, et al.,
showed that abnormal liver function tests (LFTs) were significantly
associated with a higher rate of transfer to the ICU and mortality compared
to patients with COVID-19 who did not have any LFT abnormalities.4 A few
studies have demonstrated that levels of ACE-2, the cell receptor that
SARS-CoV-2 binds to for cell entry, become upregulated by chronic
hepatobiliary disease. This theoretically could result in an increased
susceptibility to COVID infection in patients with preexisting chronic liver
disease. Additionally, significant pro-inflammatory cytokine responses
induced by the acute phase of the SARS-CoV 2 infection could
subsequently result in liver damage.5 Despite these findings, there has not
been much literature evaluating the clinical sequelae of SARS-CoV-2
infection in the setting of chronic liver disease. It is unclear whether
preexisting chronic liver disease plays a role in the progression of SARSCoV-2 disease in terms of morbidity and mortality. We believe that
evaluation of outcomes, especially mortality rates, in this subset of patients
is warranted due to the rapid and severe nature of viral infection with
COVID-19. Chronic liver disease may be a risk factor for severe clinical
outcomes.

COVID-19 Disease Symptoms:
•
Higher percentage of those in the LD group experienced GI symptoms such as nausea, vomiting, and
diarrhea
•
Alternatively, a higher percentage of the NLD group seemed to have experienced respiratory symptoms such
as cough, SOB, and hypoxia
•
Possible mechanism of GI symptom manifestation- ACE2 receptors in the small intestine
Complications:
• Patients in the NLD group were more likely to be hospitalized, but patients in the LD group were slightly more
likely to be placed in the ICU and progressed to hospice care (not statistically significant)
• With regards to the high rates of hospitalization for all our patients (51.02%) and ICU placement
(32.67%), we suggest that this could be due to the higher BMI and older age in our overall patient
cohort, resulting in a higher rate of complications
• It is possible that while treatment modalities and interventions were still being formulated, patients
had higher hospitalization and ICU placement rates in general
• Patients with liver disease were more likely to have initiation of mechanical ventilation, renal replacement
therapy, pressor initiation for low volume status, thrombotic events, or a gastrointestinal bleed (whether
variceal or not)
• None of the differences in complications between the groups were statistically significant
• Possible that the increased complication rates are due to the LD group having more comorbidities
and a decreased health status at baseline
SELECT:
•
Vulnerable populations already facing barriers to care could have been disproportionately affected by the
changes in care delivery during the pandemic
•
A study done by the University of Pennsylvania evaluated how the COVID-19 pandemic affected the volume
of nationwide cirrhosis hospitalizations, noting that many patients who suffered from liver disease lacked
proper access to care at baseline.
•
Hospital centers faced more of a challenge in managing their high risk and chronically ill patients, with some
implementing risk stratification models
•
We hope that identification of prognostic factors of COVID-19 disease severity will enable care centers to
establish a more standardized management protocol for patients with liver disease and prevent vulnerable
patients from slipping through the cracks during this tenuous time.
•
Future directions- subgroup analyses by race to understand if there are any racial disparities in relation to
outcomes from COVID-19 in patients with LD
•
From a health systems standpoint, it would also be interesting to evaluate the relationship of insurance and
socioeconomic status of our study cohort receiving care.

Problem Statement

Limitations:
•
Internal validity
•
External validity
•
Time frame to complete the study
•
89.46% of patients were censored after time frame for data collection
•
Lastly, this study was a single-center, retrospective study with a moderate sample size

In patients with active COVID-19 infection, demographic data
and characteristics of the clinical COVID-19 disease course
have not been adequately compared for patients with and
without preexisting chronic liver disease.

The overall goal of our study, in obtaining mortality and
outcome data, was to improve management of patients with
chronic liver disease at LVHN and other institutions. The
results of our study found that patients with chronic liver
disease were more likely to have comorbid conditions, such
as metabolic disease, that could predispose these patients
to more complications during the COVID infection course.
The study also found that these patients are more likely to
experience gastrointestinal symptoms than respiratory
symptoms, a finding that may help us identify possible
COVID infection for liver disease patients with those
symptoms. Longer follow up for these patients would help
strengthen our understanding of the mortality rates in
patients with and without liver disease. Further investigation
into which chronic liver disease predisposes to certain
outcomes would also be helpful to our study. Given the
high-risk nature of this population, we hope to use this
information from our study to better triage patients with liver
disease who are presenting with COVID-19 infection.

A retrospective cohort study at LVHN, evaluating 147 patients with and 147
patients without chronic liver disease, all of whom were infected with
COVID-19 during March 22nd, 2020 to August 1, 2020.
•

•

•

•

Patient Identification via EPIC tool Slicer Dicer
–
Diagnosis “COVID-19 (ICD-10-CM:U07.1)
–
Age range: “18 years or more and 100 years or less,”
–
20 slices classified by a diagnosis qualifying as chronic liver
disease were then applied to the query in Slicer Dicer.
 322 patients were identified in this list as having one or more
of these diagnoses of chronic liver disease (LD). The 6403
patients remaining were identified as not having chronic liver
disease (NLD).
Finalizing patient list
–
These two lists were propensity matched on the basis of age,
sex, and BMI and sorted into 150 pairs
–
The initial decision to review 150 patient charts per cohort was
made given the allotted time frame and what was believed to
be feasible for data collection.
 147 patients in each cohort after inclusion criteria applied
Data collection
–
Demographic and baseline clinical data was collected for
these 294 charts, as well as post-COVID-19 infection clinical
data
–
Chart review of these patients included follow-up data for 90
days after their COVID-19 diagnosis to capture 3-month
mortality
Statistics
–
Descriptive statistics for demographics and clinical data
–
Bivariate analyses- to determine if any demographics or
baseline clinical characteristics were statistically significantly
different between groups
–
Chi-square tests were used to determine if there was a
statistically significant difference in the percentage of patients
admitted to the hospital or ICU, who require mechanical
ventilation, renal replacement therapy, pressor therapy, and
30-day mortality
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